Chargement en cours...
Population pharmacokinetic and exposure simulation analysis for cediranib (AZD2171) in pooled Phase I/II studies in patients with cancer
AIMS: A population pharmacokinetic (PK) model was developed for cediranib to simulate cediranib exposure for different doses, including comedication with strong uridine glucuronosyl transferase/P‐glycoprotein inducers such as rifampicin, in cancer patients. METHODS: Plasma concentrations and covaria...
Enregistré dans:
| Publié dans: | Br J Clin Pharmacol |
|---|---|
| Auteurs principaux: | , , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
John Wiley and Sons Inc.
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5510068/ https://ncbi.nlm.nih.gov/pubmed/28213941 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bcp.13266 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|